Insight Molecular Diagnostics Inc. Common Stock (IMDX)

About IMDX

Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that asses…

Sector

Health Care

Industry

Biotechnology: In Vitro & In Vivo Diagnostic Substances

Employees

55

Website

imdxinc.com/

Fundamentals

1-day range

$4.11$4.48

Market cap

$162.42M

P/E (trailing)

—

P/E (forward)

-5.16

EPS (trailing)

$-1.48

Dividend yield

—

Beta

1.82

Avg. volume

220.8K

Forecasts

4 analyst ratings

Insight Molecular Diagnostics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• IMDX

  Insight Molecular Diagnostics Inc. Common Stock

  $4.16

  ▼ 3.03%
  Market cap $162.42MP/E —
  $2.33$8.51
• TKNO

  Alpha Teknova Inc. Common Stock

  $7.13

  ▼ 2.46%
  Market cap $284.15MP/E —
  $1.91$7.84
• CDIO

  Cardio Diagnostics Holdings Inc. Common stock

  $1.84

  ▼ 1.60%
  Market cap $4.85MP/E —
  $0.97$7.91
• BMRA

  Biomerica Inc. Common Stock

  $2.14

  ▲ 1.67%
  Market cap $4.73MP/E —
  $1.45$3.31
• VRAX

  Virax Biolabs Group Limited Ordinary Shares

  $2.82

  ▼ 4.08%
  Market cap $2.34MP/E —
  $2.5$21.75
• ACHV

  Achieve Life Sciences Inc. Common Shares

  $8.09

  ▼ 1.16%
  Market cap $648.81MP/E —
  $2.62$8.61
• NTLA

  Intellia Therapeutics Inc. Common Stock

  $12.87

  ▼ 1.83%
  Market cap $1.50BP/E —
  $7.95$28.25

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• LUCID CAPITAL MARKETS Initiates Coverage On Insight Molecular with Buy Rating, Announces Price Target of $8
  benzinga · 8/24/2026
• Needham Reiterates Buy on Insight Molecular, Maintains $9 Price Target
  Benzinga · 8/18/2026
• Insight Molecular Diagnostics Inc. (IMDX) Discusses Advances in Heart Transplant Rejection Testing and Evolution of Diagnostic Methods Transcript
  SeekingAlpha · 8/17/2026
• Insight Molecular Diagnostics To Host Virtual KOL Event On August 17 To Discuss GraftAssure Platform Leveraging Digital PCR Technology For Reliable dd-cfDNA Results In Transplanted Organ Health Monitoring
  Benzinga · 8/11/2026
• Insight Molecular Diagnostics Inc. (IMDX) Q2 2026 Earnings Call Transcript
  SeekingAlpha · 8/11/2026
• CORRECTION: Insight Molecular Q2 Adj. EPS $(0.23) Beats $(0.24) Estimate, Sales $239.000K Miss $437.500K Estimate
  Benzinga · 8/10/2026

• Andrew J. Last · July 1, 2026 · Tax Withholding

  7.7K @ $5.69
• Andrew Arno · July 1, 2026 · Tax Withholding

  12.1K @ $5.69
• Lou Silverman · July 1, 2026 · Tax Withholding

  7.7K @ $5.69
• Andrew J. Last · June 11, 2026 · Grant

  26.9K
• Andrew Arno · June 11, 2026 · Grant

  32.3K
• Lou Silverman · June 11, 2026 · Grant

  26.9K
• BROADWOOD PARTNERS, L.P. · April 27, 2026 · Buy

  0
• BROADWOOD PARTNERS, L.P. · April 27, 2026 · Buy

  250.9K @ $3.64
• BROADWOOD PARTNERS, L.P. · April 24, 2026 · Buy

  0
• BROADWOOD PARTNERS, L.P. · April 24, 2026 · Buy

  38.9K @ $3.53
• BROADWOOD PARTNERS, L.P. · April 23, 2026 · Buy

  0
• BROADWOOD PARTNERS, L.P. · April 23, 2026 · Buy

  280.4K @ $3.5
• BROADWOOD PARTNERS, L.P. · April 20, 2026 · Buy

  0
• BROADWOOD PARTNERS, L.P. · April 20, 2026 · Buy

  40.7K @ $3.88
• BROADWOOD PARTNERS, L.P. · April 17, 2026 · Buy

  0

Institutional Ownership

March 31, 2026

Total shares held

18.80M

Total value held

$60.85M

Institutional holders

38